Fundamentos de EBS
visão geral do detalhamento das receitas de Emergent BioSolutions Inc.
A receita de Emergent BioSolutions Inc. no último ano foi de 1.04 B USD, a maior parte da qual — 509.80 M USD — veio da sua fonte de melhor performance no momento, Medical Countermeasures Products, que no ano anterior gerou 447.20 M USD. A maior contribuição para o valor da receita foi feito por Estados Unidos — que ano anterior gerou para Emergent BioSolutions Inc. 822.60 M USD, e no ano anterior a esse — 607.20 M USD.
Por fonte
2017
2018
2019
2020
2021
2022
2023
2024
0,00
500,00 M
1,00 B
1,50 B
2,00 B
Medical Countermeasures Products
Commercial Products
Services
Reconciling Items
Government - Medical Countermeasures and Commercial Product
Contract Development and Manufacturing Services
Nasal Naloxone Products
Contract Development and Manufacturing - Services
Contract Development and Manufacturing - Leases
Anthrax Vaccines
ACAM2000
Other
Moeda: USD
2017
2018
2019
2020
2021
2022
2023
2024
Medical Countermeasures Products
—
—
—
447,20 M
509,80 M
Commercial Products
—
—
—
497,30 M
398,90 M
Services
—
—
—
78,50 M
104,90 M
Reconciling Items
115,10 M
134,20 M
41,40 M
26,30 M
30,00 M
Government - Medical Countermeasures and Commercial Product
—
—
966,20 M
—
—
Contract Development and Manufacturing Services
450,50 M
—
113,30 M
—
—
Nasal Naloxone Products
311,20 M
434,30 M
—
—
—
Contract Development and Manufacturing - Services
—
334,90 M
—
—
—
Contract Development and Manufacturing - Leases
—
299,70 M
—
—
—
Anthrax Vaccines
373,80 M
259,80 M
—
—
—
ACAM2000
200,30 M
206,50 M
—
—
—
Other
104,50 M
123,30 M
—
—
—
Por país
2017
2018
2019
2020
2021
2022
2023
2024
0,00
500,00 M
1,00 B
1,50 B
2,00 B
United States
Canada
Other
Moeda: USD
2017
2018
2019
2020
2021
2022
2023
2024
United States
1,45 B
1,65 B
889,50 M
607,20 M
822,60 M
Canada
—
—
148,60 M
224,20 M
140,40 M
Other
108,88 M
143,42 M
82,80 M
217,90 M
80,60 M